Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

e@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 16 CEL-SCI Corporation (NYSE Amex: ... prevention and treatment of infectious diseases and a late-stage oncology ... (FDA) has indicated that the Company can proceed with its ... LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 ...
... , , EAST BRUNSWICK, N.J. Sept. 16 ... on September 14, 2009, the Company completed a Type A meeting with ... Letter (CRL) received by Savient on July 31, 2009 regarding the Company,s ... gout in patients refractory to conventional therapy. , ...
... ... FDA, including increased scrutiny of complex medical devices, automating your QA process is more ... one of the leading medical device software engineering and QA consulting firms in the ... , ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: